486 related articles for article (PubMed ID: 27846466)
1. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
2. Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Michishita I
J Atheroscler Thromb; 2016 Jul; 23(7):848-56. PubMed ID: 26797266
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
[TBL] [Abstract][Full Text] [Related]
4. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
Cariou B; Guérin P; Le May C; Letocart V; Arnaud L; Guyomarch B; Pichelin M; Probst V
Diabetes Metab; 2017 Dec; 43(6):529-535. PubMed ID: 28865748
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease.
Krychtiuk KA; Lenz M; Hohensinner P; Distelmaier K; Schrutka L; Kastl SP; Huber K; Dostal E; Oravec S; Hengstenberg C; Wojta J; Speidl WS
J Clin Lipidol; 2021; 15(3):512-521. PubMed ID: 33789832
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
Panahi Y; Ghahrodi MS; Jamshir M; Safarpour MA; Bianconi V; Pirro M; Farahani MM; Sahebkar A
Clin Biochem; 2019 Dec; 74():12-18. PubMed ID: 31493378
[TBL] [Abstract][Full Text] [Related]
7. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
8. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
Nose D; Shiga Y; Ueda Y; Idemoto Y; Tashiro K; Suematsu Y; Kuwano T; Kitajima K; Saku K; Miura SI
Heart Vessels; 2019 Jan; 34(1):19-28. PubMed ID: 29974199
[TBL] [Abstract][Full Text] [Related]
9. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
[TBL] [Abstract][Full Text] [Related]
10. Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
Wang S; Cheng ZY; Zhao ZN; Quan XQ; Wei Y; Xia DS; Li JQ; Hu JL
Eur Rev Med Pharmacol Sci; 2016; 20(6):1135-9. PubMed ID: 27049268
[TBL] [Abstract][Full Text] [Related]
11. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
[TBL] [Abstract][Full Text] [Related]
12. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Liu G; Dong Q; Li JJ
Ann Med; 2015; 47(5):386-93. PubMed ID: 26153823
[TBL] [Abstract][Full Text] [Related]
14. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
[TBL] [Abstract][Full Text] [Related]
15. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
16. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
[TBL] [Abstract][Full Text] [Related]
17. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy.
Kuyama N; Kataoka Y; Takegami M; Nishimura K; Harada-Shiba M; Hori M; Ogura M; Otsuka F; Asaumi Y; Noguchi T; Tsujita K; Yasuda S
J Am Heart Assoc; 2021 Jun; 10(11):e019525. PubMed ID: 33998287
[TBL] [Abstract][Full Text] [Related]
18. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
19. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
[TBL] [Abstract][Full Text] [Related]
20. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
Zhang Y; Zhu CG; Xu RX; Li S; Guo YL; Sun J; Li JJ
J Clin Lipidol; 2014; 8(5):494-500. PubMed ID: 25234562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
